<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OncoTargets and Therapy</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25945061</article-id><article-id pub-id-type="pmc">4408957</article-id><article-id pub-id-type="doi">10.2147/OTT.S81837</article-id><article-id pub-id-type="publisher-id">ott-8-893</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qianqian</given-names></name><xref ref-type="aff" rid="af1-ott-8-893">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhehai</given-names></name><xref ref-type="aff" rid="af2-ott-8-893">2</xref><xref ref-type="corresp" rid="c1-ott-8-893"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="af2-ott-8-893">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Liyan</given-names></name><xref ref-type="aff" rid="af2-ott-8-893">2</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="af2-ott-8-893">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Minmin</given-names></name><xref ref-type="aff" rid="af1-ott-8-893">1</xref></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Shu</given-names></name><xref ref-type="aff" rid="af1-ott-8-893">1</xref></contrib><contrib contrib-type="author"><name><surname>Bi</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="af1-ott-8-893">1</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="af1-ott-8-893">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="af1-ott-8-893">1</xref></contrib></contrib-group><aff id="af1-ott-8-893"><label>1</label>School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, University of Jinan, People&#x02019;s Republic of China</aff><aff id="af2-ott-8-893"><label>2</label>Department of Oncology, Shandong Cancer Hospital, Jinan, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-ott-8-893">Correspondence: Zhehai Wang, Department of Oncology, Shandong Cancer Hospital, 440 Jiyan Road, Huaiyin, Jinan, Shandong 250117, People&#x02019;s Republic of China, Tel/fax +86 531 6762 6331, Email <email>wzhai8778@sina.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>20</day><month>4</month><year>2015</year></pub-date><volume>8</volume><fpage>893</fpage><lpage>898</lpage><permissions><copyright-statement>&#x000a9; 2015 Zhang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2015</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>The aim of this study was to compare single-agent chemotherapy with targeted therapy in initial treatment and to explore a better choice of treatment for patients aged 80 years and older with advanced non-small-cell lung cancer (NSCLC).</p></sec><sec><title>Patients and methods</title><p>A retrospective chart review was conducted for 136 patients aged 80 years and older who were cytopathologically diagnosed and staged as advanced (stage IIIB or IV) NSCLC. The patient population was divided into two treatment groups: 78 patients were allocated to the chemotherapy group (group A, pemetrexed or gemcitabine or docetaxel as a single agent), and 60 patients were allocated to another group and received epidermal growth factor-receptor tyrosine-kinase inhibitors (group B, erlotinib or gefitinib as a single agent). The primary end points were overall survival (OS) and progression-free survival (PFS), and the secondary end points were response rate, disease-control rate, safety, and quality of life.</p></sec><sec><title>Results</title><p>In group A and group B, respectively, the median PFS was 2 versus 4 months (<italic>P</italic>=0.013), and the median OS was 8 versus 16 months (<italic>P</italic>=0.025). The 1- and 2-year survival rates of the two groups were 23.7% (group A, 18 of 76) versus 76.7% (group B, 46 of 60) and 13.2% (group A, ten of 76) versus 10% (group B, six of 60), respectively. The response rate and disease-control rate were 28.9% versus 36.7% (<italic>P</italic>=0.39) and 57.9% versus 76.7% (<italic>P</italic>=0.022) in group A and group B, respectively.</p></sec><sec><title>Conclusion</title><p>Elders aged 80 years and over with advanced NSCLC in group B had longer PFS and OS compared with group A. It was well tolerated in group B because of the mild adverse effects. Targeted therapy can be considered primarily for patients aged 80 years and older with advanced NSCLC who cannot tolerate chemotherapy or radiotherapy.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>non-small-cell lung cancer</kwd><kwd>elderly</kwd><kwd>80 years old</kwd><kwd>first-line</kwd><kwd>chemotherapy</kwd><kwd>targeted therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Lung cancer is one of the most common malignant tumors in both Western and Asian countries, and remains the major cause of cancer-related death in the world.<xref rid="b1-ott-8-893" ref-type="bibr">1</xref> Accounting for about 80% of the total number of lung cancers is non-small-cell lung cancer (NSCLC).<xref rid="b2-ott-8-893" ref-type="bibr">2</xref> However, approximately 40%&#x02013;50% of these patients present with incurable metastatic (stage IV) disease.<xref rid="b3-ott-8-893" ref-type="bibr">3</xref></p><p>As the population ages, elderly lung cancer cases show an increasing trend. It is estimated that more than half of 500,000 patients with lung cancer diagnosed each year are older than 70 years.<xref rid="b4-ott-8-893" ref-type="bibr">4</xref> Obviously, lung cancer in elders is an increasingly common problem faced by the oncologist. Elders present particularity with a variety of chronic diseases, and their status score is decreased; another feature is the loss of organ-function reserve, which will lead to tolerance differences on treatment.<xref rid="b5-ott-8-893" ref-type="bibr">5</xref> A number of retrospective analyses of trials have shown a survival benefit with platinum-based combination chemotherapy in patients aged 70 years and over.<xref rid="b6-ott-8-893" ref-type="bibr">6</xref> A study for unfit elderly patients over 70 years with advanced NSCLC indicated that single-agent chemotherapy should be considered the standard treatment, and such targeted therapies as epidermal growth-factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs), if approved for use in the future, also in the first-line treatment of this group of patients.<xref rid="b7-ott-8-893" ref-type="bibr">7</xref> In the NEJ 003 study,<xref rid="b8-ott-8-893" ref-type="bibr">8</xref> Maemondo et al demonstrated that first-line gefitinib may be preferable to standard chemotherapy for patients aged 75 years or older with NSCLC harboring EGFR mutations.</p><p>It is still not clear whether these studies mentioned in the previous paragraph apply to patients aged 80 years and over with advanced NSCLC. People aged from 80 to 89 years are known as octogenarians. With prolongation of life expectancy, the incidence of octogenarians with lung cancer is increasing year by year. The life expectancies of 80-year-old men and women are 87.3 years and 89.0 years, respectively, but NSCLC may rob them of many years of meaningful life in addition to causing morbidity.<xref rid="b9-ott-8-893" ref-type="bibr">9</xref> Seeking a suitable treatment for this age group of patients is of great significance to prolong survival and improve quality of life. However, because of octogenarians&#x02019; poor physical condition, too few elderly patients aged over 80 years were included in previous clinical trials to make any conclusions regarding this group of patients. In this instance, studies specifically focusing on these elderly patients are required. A total of 136 patients aged 80 years and older diagnosed with advanced NSCLC in Shandong Cancer Hospital were enrolled and retrospectively analyzed.</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec sec-type="subjects"><title>Patients</title><p>A total of 136 patients who had been cytopathologically diagnosed with advanced NSCLC and treated at Shandong Cancer Hospital from January 2010 to January 2013 were enrolled in this study and analyzed retrospectively. Eligibility criteria were: male or female with cytopathologically diagnosed stage IIIB or IV NSCLC aged 80 years or older, chemotherapy-na&#x000ef;ve for this stage of the disease, at least one measurable lesion by computed tomography according to World Health Organization criteria,<xref rid="b10-ott-8-893" ref-type="bibr">10</xref> an Eastern Collaborative Oncology Group (ECOG) performance status of 0&#x02013;2, and life expectancy of at least 4 months.</p></sec><sec><title>Assessment</title><p>The primary end points of the study were progression-free survival (PFS) and overall survival (OS). PFS was refers to the time from patients receiving the first-line therapy to disease progression or death. OS was measured from the first-line treatment-decision day to the day of death or the day of last follow-up. We did follow-up on all patients, and the last one was in January 2015. Secondary efficacy analyses were response rate (RR) and disease-control rate (DCR), determined by the Response Evaluation Criteria in Solid Tumors:<xref rid="b11-ott-8-893" ref-type="bibr">11</xref> complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). RR was defined as CR plus PR, and DCR was defined as CR plus PR and SD. Toxicities were graduated according to the National Cancer Institute Common Toxicity Criteria 3.0.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>We analyzed the statistics with SPSS 17.0 software (SPSS, Chicago, IL, USA). All analyses were two-sided with a 5% significance level. The primary object was to assess the OS and PFS between the two groups in this analysis. For the OS and PFS analysis, we used Kaplan&#x02013;Meier curves and the log-rank test for comparisons. RR and DCR were compared between the two groups with the <italic>&#x003c7;</italic><sup>2</sup> test. A Cox proportional hazard analysis was done to calculate hazard ratios (95% confidence interval [CI]). Covariates included sex, histology, stage, ECOG performance status, weight loss, and smoking status.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro"><title>Patient characteristics</title><p>Between January 2010 and January 2013, a total of 136 patients were enrolled in the research. The likelihood of patients aged 80 years and older being treated with single-agent chemotherapy compared with patients treated by EGFR TKIs is presented here. The median age was 82 (range 80&#x02013;92) years, with 30.9% being female. Baseline characteristics were well balanced between the two 80-and-older groups from this study except histology (<xref ref-type="table" rid="t1-ott-8-893">Table 1</xref>). A total of 78 cases of the total 136 patients received single-agent chemotherapy in group A, with gemcitabine or single pemetrexed or docetaxel regimens administered in 38 (50.0%), 26 (34.2%), and 12 (15.8%) patients as first-line treatment, respectively. The general course was for four to six cycles. Patients with EGFR mutations in group B received gefitinib (76.7%) or erlotinib (23.3%) as first-line therapy, administered until progressive disease.</p></sec><sec><title>Efficacy</title><p>All 136 patients with advanced NSCLC were able to be evaluated for efficacy. Responses to treatment for patients aged 80 years and over are displayed in <xref ref-type="table" rid="t2-ott-8-893">Table 2</xref>. RR was similar in group A and group B (RR 28.9% versus 36.7%, <italic>P</italic>=0.399). Disease control was obtained in 44 (57.8%) versus 46 (76.7%) of patients in group A and group B (<italic>P</italic>=0.022), respectively. Patients who received EGFR TKIs had significantly improved DCR (<italic>P</italic>=0.022). There were no differences in RR or DCR when gemcitabine, pemetrexed and docetaxel treatment were compared (RR 26.3% versus 30.8%, 33.3%, <italic>P</italic>=0.868; DCR 63.2% versus 61.5%, 50%, <italic>P</italic>=0.713, respectively), and similar results were obtained when erlotinib and gefitinib were compared in subgroup analysis (RR 33.3% versus 44.4%, <italic>P</italic>=0.413; DCR 76.2% versus 77.8%, <italic>P</italic>=0.894; respectively). In a subgroup analysis, patients with adenocarcinoma in the two groups had no differences in RR (<italic>P</italic>=0.965) or DCR (<italic>P</italic>=0.313).</p></sec><sec><title>Survival</title><p>Median PFS was 2 months (95% CI 1.49&#x02013;2.515 months) with chemotherapy versus 4 months (95% CI 4.3&#x02013;9.5 months) with EGFR TKIs (<italic>P</italic>=0.013). When we compared OS between the two groups, this was 8 months (95% CI 7.10&#x02013;8.89 months) in group A and 16 months (95% CI 13.17&#x02013;18.83 months) in group B (<italic>P</italic>=0.025). The 1- and 2-year survival rates of the two groups were 23.7% in group A versus 76.7% in group B (<italic>P</italic>&#x0003c;0.001), and 13.2% in group A versus 10% in group B (<italic>P</italic>=0.605), respectively. In subgroup analysis, patients with adenocarcinoma in group B had a higher 1-year survival rate compared with group A (29.4% in group A versus 66.7% in group B, <italic>P</italic>=0.001); however, the 2 year survival rate showed no significant differences (11.7% in group A versus 8.3% in group B, <italic>P</italic>=0.89). We used Cox multivariate regression analysis to determine factors influencing survival. The results showed that ECOG performance status was an independent prognostic factor (<xref ref-type="table" rid="t3-ott-8-893">Table 3</xref>). The PFS OS curves of the two groups are shown in <xref ref-type="fig" rid="f1-ott-8-893">Figures 1</xref> and <xref ref-type="fig" rid="f2-ott-8-893">2</xref>, respectively. The efficacy of the first-line treatment is shown in <xref ref-type="table" rid="t4-ott-8-893">Table 4</xref>.</p></sec><sec><title>Safety</title><p>In general, patients were well tolerated in the two groups. The most common adverse events were hematology toxicity (61 [80%] of 76 patients at grade 1&#x02013;2) and rash (20 [47%] of 60 patients at grade 1&#x02013;2) in group A and group B, respectively. Grade 3/4 hematologic toxicity and rash were documented in eight (10%) versus two (3%) patients and 0 versus 3 (5%) patients in group A and group B, respectively. One patient in group A had grade 4 hematologic toxicity. Detailed adverse effects are displayed in <xref ref-type="table" rid="t5-ott-8-893">Table 5</xref>.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>There has been increasing interest in the treatment of elderly patients aged 80 years and older with advanced NSCLC. However, the clinical data regarding this group of patients have not been fully available, because such patients are not usually included in retrospective analysis and clinical trials, and there is still no standard treatment for patients aged 80 years and older. The present study evaluated the efficacy, survival, and feasibility of first-line EGFR TKIs and single-agent chemotherapy treatment for elderly patients aged 80 years and older. It is of great significance to show that EGFR-TKIs can prolong survival and improve quality of life.</p><p>Patients treated with EGFR TKIs had higher DCR, longer PFS and OS, and milder side effects than patients who were treated with single-agent chemotherapy in this study. Molecularly targeted therapy changed the specific characteristics of the tumor cells, but showed more potent antitumor activity and reduced the side effects on normal cells. About 40%&#x02013;85% of lung cancer tissue specimens in patients with NSCLC were detected in EGFR expression or high expression, and lesions in patients with high expression of EGFR progress more quickly and not sensitive to chemotherapy or radiotherapy as well as show poor prognosis.<xref rid="b12-ott-8-893" ref-type="bibr">12</xref> At present, gefitinib and erlotinib are the most common EGFR TKIs and are widely used in the treatment of patients with advanced NSCLC with mild adverse effects, and can significantly improve the quality of life. Considering that a large portion of elderly patients aged 80 years and older with advanced NSCLC often refuse chemotherapy,<xref rid="b13-ott-8-893" ref-type="bibr">13</xref> molecularly targeted drugs have become a new choice for this group of patients. A number of findings have shown benefit for EGFR TKIs in both Asian and European populations.<xref rid="b14-ott-8-893" ref-type="bibr">14</xref>&#x02013;<xref rid="b16-ott-8-893" ref-type="bibr">16</xref> Recent data suggest that patients with EGFR mutations should use erlotinib as first-line systemic therapy before first-line chemotherapy.<xref rid="b17-ott-8-893" ref-type="bibr">17</xref>,<xref rid="b18-ott-8-893" ref-type="bibr">18</xref> The OPTIMAL trial demonstrated that erlotinib as first-line treatment in patients harboring EGFR mutations with advanced NSCLC can significantly prolong PFS regardless of age, sex, ECOG status, stage, histological type, or smoking status, and quality of life is better than those receiving chemotherapy.<xref rid="b19-ott-8-893" ref-type="bibr">19</xref> In our study, elderly patients in the targeted therapy group achieved median PFS and OS of 4 and 16 months, respectively, which were longer when compared with the chemotherapy group (PFS 4 versus 2 months, <italic>P</italic>=0.013; OS 16 versus 8 months, <italic>P</italic>=0.025). The 1-year survival rate was higher (23.7% versus 76.7%, <italic>P</italic>&#x0003c;0.001) in group B, but something interesting was that the 2-year survival rate showed no significant difference (13.2% versus 10%, <italic>P</italic>=0.605), perhaps because of insufficient cases. The number of patients with adenocarcinoma in the targeted group was larger than in the chemotherapy group. Because the enrolled cases were so few, the compared groups could not be completely randomized or controlled. Another reason is that EGFR TKIs are suitable for patients with adenocarcinoma who harbor EGFR mutations. A subgroup analysis showed that patients with adenocarcinoma in the two groups showed no differences in RR (<italic>P</italic>=0.965) or DCR (<italic>P</italic>=0.313). Patients had a higher 1-year survival rate in group B compared with group A (29.4% in group A versus 66.7% in group B, <italic>P</italic>=0.001); however, the 2-year survival rate showed no significant difference (11.7% in group A versus 8.3% in group B, <italic>P</italic>=0.89). Therefore, patients aged 80 years and older with adenocarcinoma benefit from EGFR-TKI than chemotherapy. In group B, the main adverse effect was rash and mostly were grade I&#x02013;II. Three patients (5%) got a grade III rash which patients were well tolerated.</p><p>In most patients aged 70&#x02013;79 years with advanced NSCLC, single-agent chemotherapy is the standard treatment,<xref rid="b20-ott-8-893" ref-type="bibr">20</xref> but data on patients aged 80 years and over were not mentioned. The joint SWOG0027 and LUN6 trials studied elderly patients aged 80 years and older with advanced NSCLC receiving chemotherapy, and the results showed encouraging disease efficiency (RR 53%) and the treatment was well tolerated.<xref rid="b21-ott-8-893" ref-type="bibr">21</xref> In our study, the RR (28.9%) in the chemotherapy group was lower than in the trial, and the OS of 8 months with single-agent chemotherapy also shorter than data previously reported for patients aged below 80 years with advanced NSCLC.<xref rid="b22-ott-8-893" ref-type="bibr">22</xref> Maybe the reason for single-agent chemotherapy reduced the curative effects,<xref rid="b23-ott-8-893" ref-type="bibr">23</xref> and for the loss of organ reserve function made poor tolerance to chemotherapy. Although the results of chemotherapy-treated elderly patients with advanced NSCLC have been unsatisfactory, chemotherapy can prolong survival and improve quality of life when compared with best supportive care in previous research.<xref rid="b24-ott-8-893" ref-type="bibr">24</xref> The adverse reactions of patients in group A were akin to reported data of patients aged below 80 years,<xref rid="b25-ott-8-893" ref-type="bibr">25</xref> and the application of single-agent chemotherapy reduced toxicity of drugs probably. Patients treated with single-agent chemotherapy showed good tolerance.</p><p>In this study, we noted differences in OS, PFS, and DCR between the two groups. Multifactorial analysis revealed that performance status was strongly related to survival, and this is consistent with the results of previous research.<xref rid="b26-ott-8-893" ref-type="bibr">26</xref> We recommend that elderly patients with ECOG status &#x02264;2 receive medical treatment. The study results reinforce the feasibility of upfront genotyping of patients and the improved results attained with therapy directed against a known target. By comparing the data of the two groups, we propose that for patients aged 80 years and older diagnosed with NSCLC, the feasibility of application of TKIs should be considered first. Then, gene detection is suggested for this group of patients. We suggest that patients with activating EGFR mutations should receive EGFR-TKIs. Quality of life can be obviously improved with EGFR-TKIs due to the mild side-effects. EGFR-TKI is more suitable than chemotherapy for patients aged 80 years and older with NSCLC who harboring EGFR mutations. For patients with wild-type EGFR with good ECOG status (&#x0003c;2), age should not become an obstacle to receiving chemotherapy. In order to avoid toxicities and disease control for this group of patients, we suggest the application of single-agent chemotherapy starting with a small dose, and for doses to be altered according to specific circumstances.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ott-8-893"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quoix</surname><given-names>E</given-names></name><name><surname>Ramlau</surname><given-names>R</given-names></name><name><surname>Westeel</surname><given-names>V</given-names></name><etal/></person-group><article-title>Therapeutic vaccination with tg4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>1125</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">22019520</pub-id></element-citation></ref><ref id="b2-ott-8-893"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le P&#x000e9;choux</surname><given-names>C</given-names></name></person-group><article-title>Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data</article-title><source>Oncologist</source><year>2011</year><volume>16</volume><fpage>672</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">21378080</pub-id></element-citation></ref><ref id="b3-ott-8-893"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ihde</surname><given-names>DC</given-names></name></person-group><article-title>Chemotherapy of lung cancer</article-title><source>N Engl J Med</source><year>1992</year><volume>327</volume><fpage>1434</fpage><lpage>1441</lpage><pub-id pub-id-type="pmid">1328881</pub-id></element-citation></ref><ref id="b4-ott-8-893"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frusch</surname><given-names>N</given-names></name><name><surname>Bosquee</surname><given-names>L</given-names></name><name><surname>Louis</surname><given-names>R</given-names></name></person-group><article-title>lung cancer epidemiology and etiologic factors</article-title><source>Rev Med Liege</source><year>2007</year><volume>62</volume><issue>9</issue><fpage>548</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">17966790</pub-id></element-citation></ref><ref id="b5-ott-8-893"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>J</given-names></name><name><surname>Stinchcombe</surname><given-names>TE</given-names></name></person-group><article-title>Treatment of elderly patients with stage IV non-small-cell lung cancer</article-title><source>Expert Rev Anticancer Ther</source><year>2012</year><volume>12</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">22149437</pub-id></element-citation></ref><ref id="b6-ott-8-893"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gridelli</surname><given-names>C</given-names></name><name><surname>Aapro</surname><given-names>M</given-names></name><name><surname>Ardizzoni</surname><given-names>A</given-names></name><etal/></person-group><article-title>Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>3125</fpage><lpage>3137</lpage><pub-id pub-id-type="pmid">15860872</pub-id></element-citation></ref><ref id="b7-ott-8-893"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gridelli</surname><given-names>C</given-names></name><name><surname>Maione</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Palazzolo</surname><given-names>G</given-names></name><name><surname>Colantuoni</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>E</given-names></name></person-group><article-title>Management of unfit older patients with advanced NSCLC</article-title><source>Cancer Treat Rev</source><year>2009</year><volume>35</volume><fpage>517</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">19457617</pub-id></element-citation></ref><ref id="b8-ott-8-893"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maemondo</surname><given-names>M</given-names></name><name><surname>Minegishi</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><etal/></person-group><article-title>First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study</article-title><source>J Thorac Oncol</source><year>2012</year><volume>7</volume><fpage>1417</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">22895139</pub-id></element-citation></ref><ref id="b9-ott-8-893"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altundag</surname><given-names>O</given-names></name><name><surname>Stewart</surname><given-names>DJ</given-names></name><name><surname>Fossella</surname><given-names>FV</given-names></name><etal/></person-group><article-title>Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy</article-title><source>J Thorac Oncol</source><year>2007</year><volume>2</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">17410030</pub-id></element-citation></ref><ref id="b10-ott-8-893"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Hoogstraten</surname><given-names>B</given-names></name><name><surname>Staquet</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>A</given-names></name></person-group><article-title>Reporting results of cancer treatment</article-title><source>Cancer</source><year>1981</year><volume>47</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">7459811</pub-id></element-citation></ref><ref id="b11-ott-8-893"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><etal/></person-group><article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">10655437</pub-id></element-citation></ref><ref id="b12-ott-8-893"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name><etal/></person-group><article-title>Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors</article-title><source>Cold Spring Harb Symp Quant Biol</source><year>2005</year><volume>70</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">16869779</pub-id></element-citation></ref><ref id="b13-ott-8-893"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>ML</given-names></name><name><surname>Hamilton</surname><given-names>N</given-names></name><name><surname>Davoren</surname><given-names>JB</given-names></name><name><surname>Jahan</surname><given-names>TM</given-names></name><name><surname>Walter</surname><given-names>LC</given-names></name></person-group><article-title>Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1447</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">22454424</pub-id></element-citation></ref><ref id="b14-ott-8-893"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20022809</pub-id></element-citation></ref><ref id="b15-ott-8-893"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maemondo</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>2380</fpage><lpage>2388</lpage><pub-id pub-id-type="pmid">20573926</pub-id></element-citation></ref><ref id="b16-ott-8-893"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>TS</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>947</fpage><lpage>957</lpage><pub-id pub-id-type="pmid">19692680</pub-id></element-citation></ref><ref id="b17-ott-8-893"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Carcereny</surname><given-names>E</given-names></name><name><surname>Gervais</surname><given-names>R</given-names></name><etal/></person-group><article-title>Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">22285168</pub-id></element-citation></ref><ref id="b18-ott-8-893"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC)</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>Suppl 15</issue><fpage>7520</fpage></element-citation></ref><ref id="b19-ott-8-893"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">21783417</pub-id></element-citation></ref><ref id="b20-ott-8-893"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socinski</surname><given-names>MA</given-names></name><name><surname>Crowell</surname><given-names>R</given-names></name><name><surname>Hensing</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)</article-title><source>Chest</source><year>2007</year><volume>132</volume><fpage>277S</fpage><lpage>289S</lpage><pub-id pub-id-type="pmid">17873174</pub-id></element-citation></ref><ref id="b21-ott-8-893"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hesketh</surname><given-names>PJ</given-names></name><name><surname>Lilenbaum</surname><given-names>RC</given-names></name><name><surname>Chansky</surname><given-names>K</given-names></name><etal/></person-group><article-title>Chemotherapy in patients &#x02265;80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6</article-title><source>J Thorac Oncol</source><year>2007</year><volume>2</volume><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">17545843</pub-id></element-citation></ref><ref id="b22-ott-8-893"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semrau</surname><given-names>S</given-names></name><name><surname>Zettl</surname><given-names>H</given-names></name><name><surname>Hildebrandt</surname><given-names>G</given-names></name><name><surname>Klautke</surname><given-names>G</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name></person-group><article-title>Older patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapy</article-title><source>Strahlenther Onkol</source><year>2014</year><volume>190</volume><fpage>1125</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">25098688</pub-id></element-citation></ref><ref id="b23-ott-8-893"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>WX</given-names></name><name><surname>Tang</surname><given-names>LN</given-names></name><name><surname>He</surname><given-names>AN</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name></person-group><article-title>Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis</article-title><source>Lung</source><year>2012</year><volume>190</volume><fpage>477</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">22711060</pub-id></element-citation></ref><ref id="b24-ott-8-893"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Sekine</surname><given-names>I</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small-cell lung cancer patients</article-title><source>J Thorac Oncol</source><year>2008</year><volume>3</volume><fpage>412</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">18379361</pub-id></element-citation></ref><ref id="b25-ott-8-893"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guckenberger</surname><given-names>M</given-names></name><name><surname>Kavanagh</surname><given-names>A</given-names></name><name><surname>Partridge</surname><given-names>M</given-names></name></person-group><article-title>Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer</article-title><source>Strahlenther Onkol</source><year>2012</year><volume>188</volume><fpage>894</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">22933031</pub-id></element-citation></ref><ref id="b26-ott-8-893"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breen</surname><given-names>D</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Zemerli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Results and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged &#x0003e;80 years</article-title><source>Clin Lung Cancer</source><year>2007</year><volume>8</volume><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">17562233</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ott-8-893" position="float"><label>Figure 1</label><caption><p>Progression-free survival (PFS) in first-line treatment.</p></caption><graphic xlink:href="ott-8-893Fig1"/></fig><fig id="f2-ott-8-893" position="float"><label>Figure 2</label><caption><p>Overall survival (OS) in first-line treatment.</p></caption><graphic xlink:href="ott-8-893Fig2"/></fig><table-wrap id="t1-ott-8-893" position="float"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">Group A (n=76)</th><th valign="top" align="left" rowspan="1" colspan="1">Group B (n=60)</th></tr></thead><tbody><tr><td colspan="3" valign="top" align="left" rowspan="1">Sex</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">22 (28.9%)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (33.3%)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Age, years</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Median (range)</td><td valign="top" align="left" rowspan="1" colspan="1">82 (80&#x02013;86)</td><td valign="top" align="left" rowspan="1" colspan="1">83 (80&#x02013;92)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Histology</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Squamous cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">36 (47.4%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">34 (44.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (80%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Large-cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">6 (7.9%)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (15%)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Stage</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IIIB</td><td valign="top" align="left" rowspan="1" colspan="1">34 (44.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (60%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IV</td><td valign="top" align="left" rowspan="1" colspan="1">42 (55.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (40%)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">ECOG PS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;0</td><td valign="top" align="left" rowspan="1" colspan="1">4 (5.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (6.7%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;1</td><td valign="top" align="left" rowspan="1" colspan="1">58 (76.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (76.6%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;2</td><td valign="top" align="left" rowspan="1" colspan="1">14 (18.4%)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (16.7%)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Weight loss &#x02265;5%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">62 (81.6%)</td><td valign="top" align="left" rowspan="1" colspan="1">44 (73.3%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">14 (18.4%)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (26.7%)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Smoking status</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Current</td><td valign="top" align="left" rowspan="1" colspan="1">36 (47.4%)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (30.0%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Former</td><td valign="top" align="left" rowspan="1" colspan="1">23 (30.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (36.7%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Never</td><td valign="top" align="left" rowspan="1" colspan="1">17 (22.4%)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (33.3%)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ott-8-893"><p><bold>Abbreviations:</bold> ECOG, Eastern Cooperative Oncology Group; PS, performance status.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ott-8-893" position="float"><label>Table 2</label><caption><p>Response among patients aged 80 years and over with non-small-cell lung cancer to first-line treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Total (n=136), n (%)</th><th valign="top" align="left" rowspan="1" colspan="1">Group A (n=76), n (%)</th><th valign="top" align="left" rowspan="1" colspan="1">Group B (n=60), n (%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">CR</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PR</td><td valign="top" align="left" rowspan="1" colspan="1">44 (32.4)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (28.9)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (36.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SD</td><td valign="top" align="left" rowspan="1" colspan="1">46 (33.8)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (28.9)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (40)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PD</td><td valign="top" align="left" rowspan="1" colspan="1">46 (33.8)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (42.1)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (23.3)</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ott-8-893"><p><bold>Abbreviations:</bold> CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ott-8-893" position="float"><label>Table 3</label><caption><p>Cox proportional hazard model for progression-free survival and overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Factors</th><th colspan="3" valign="top" align="left" rowspan="1">Progression-free survival
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Overall survival
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic></th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1">1.175</td><td valign="top" align="left" rowspan="1" colspan="1">0.768&#x02013;1.797</td><td valign="top" align="left" rowspan="1" colspan="1">0.456</td><td valign="top" align="left" rowspan="1" colspan="1">0.927</td><td valign="top" align="left" rowspan="1" colspan="1">0.605&#x02013;1.420</td><td valign="top" align="left" rowspan="1" colspan="1">0.728</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Histology</td><td valign="top" align="left" rowspan="1" colspan="1">0.728</td><td valign="top" align="left" rowspan="1" colspan="1">0.516&#x02013;1.027</td><td valign="top" align="left" rowspan="1" colspan="1">0.071</td><td valign="top" align="left" rowspan="1" colspan="1">0.827</td><td valign="top" align="left" rowspan="1" colspan="1">0.571&#x02013;1.197</td><td valign="top" align="left" rowspan="1" colspan="1">0.314</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage</td><td valign="top" align="left" rowspan="1" colspan="1">1.107</td><td valign="top" align="left" rowspan="1" colspan="1">0.757&#x02013;1.620</td><td valign="top" align="left" rowspan="1" colspan="1">0.599</td><td valign="top" align="left" rowspan="1" colspan="1">1.111</td><td valign="top" align="left" rowspan="1" colspan="1">0.753&#x02013;1.640</td><td valign="top" align="left" rowspan="1" colspan="1">0.594</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking status</td><td valign="top" align="left" rowspan="1" colspan="1">1.119</td><td valign="top" align="left" rowspan="1" colspan="1">0.883&#x02013;1.418</td><td valign="top" align="left" rowspan="1" colspan="1">0.351</td><td valign="top" align="left" rowspan="1" colspan="1">0.851</td><td valign="top" align="left" rowspan="1" colspan="1">0.674&#x02013;1.074</td><td valign="top" align="left" rowspan="1" colspan="1">0.174</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight loss &#x02265;5%</td><td valign="top" align="left" rowspan="1" colspan="1">1.602</td><td valign="top" align="left" rowspan="1" colspan="1">0.666&#x02013;1.695</td><td valign="top" align="left" rowspan="1" colspan="1">0.800</td><td valign="top" align="left" rowspan="1" colspan="1">1.165</td><td valign="top" align="left" rowspan="1" colspan="1">0.672&#x02013;2.020</td><td valign="top" align="left" rowspan="1" colspan="1">0.586</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ECOG score</td><td valign="top" align="left" rowspan="1" colspan="1">2.773</td><td valign="top" align="left" rowspan="1" colspan="1">1.795&#x02013;4.285</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">2.531</td><td valign="top" align="left" rowspan="1" colspan="1">1.647&#x02013;3.889</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ott-8-893"><p><bold>Abbreviations:</bold> ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ott-8-893" position="float"><label>Table 4</label><caption><p>Efficacy of first-line treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Group 1<break/>(n=76)</th><th valign="top" align="left" rowspan="1" colspan="1">Group 2<break/>(n=60)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Response rate</td><td valign="top" align="left" rowspan="1" colspan="1">28.9%</td><td valign="top" align="left" rowspan="1" colspan="1">36.7%</td><td valign="top" align="left" rowspan="1" colspan="1">0.399</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Disease-control rate</td><td valign="top" align="left" rowspan="1" colspan="1">57.9%</td><td valign="top" align="left" rowspan="1" colspan="1">76.7%</td><td valign="top" align="left" rowspan="1" colspan="1">0.022</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Progression free survival</td><td valign="top" align="left" rowspan="1" colspan="1">2 months</td><td valign="top" align="left" rowspan="1" colspan="1">4 months</td><td valign="top" align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Overall survival</td><td valign="top" align="left" rowspan="1" colspan="1">8 months</td><td valign="top" align="left" rowspan="1" colspan="1">16 months</td><td valign="top" align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1-year survival rate</td><td valign="top" align="left" rowspan="1" colspan="1">23.7%</td><td valign="top" align="left" rowspan="1" colspan="1">76.7%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2-year survival rate</td><td valign="top" align="left" rowspan="1" colspan="1">13.2%</td><td valign="top" align="left" rowspan="1" colspan="1">10%</td><td valign="top" align="left" rowspan="1" colspan="1">0.605</td></tr></tbody></table></table-wrap><table-wrap id="t5-ott-8-893" position="float"><label>Table 5</label><caption><p>Common adverse events in the safety population, n (%)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">Group 1 (n=76)
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Group 2 (n=60)
<hr/></th></tr><tr><th colspan="3" valign="top" align="left" rowspan="1">Grade
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Grade
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">1&#x02013;2</th><th valign="top" align="left" rowspan="1" colspan="1">3</th><th valign="top" align="left" rowspan="1" colspan="1">4</th><th valign="top" align="left" rowspan="1" colspan="1">1&#x02013;2</th><th valign="top" align="left" rowspan="1" colspan="1">3</th><th valign="top" align="left" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Fatigue</td><td valign="top" align="left" rowspan="1" colspan="1">53 (70)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (7)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">18 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rash</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">28 (47)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Appetite loss</td><td valign="top" align="left" rowspan="1" colspan="1">39 (51)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (7)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">12 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vomiting</td><td valign="top" align="left" rowspan="1" colspan="1">9 (12)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hematology toxicity</td><td valign="top" align="left" rowspan="1" colspan="1">61 (80)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (9)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></floats-group></article>